At the news
? BULLISHIMPACT 8/10 8-K filed Aug 25, 2026 at 10:54 ET
Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii)-containing regimens for first-line HER2+ gastroesophageal adenocarcinoma (GEA). This approval triggers a $250 million milestone payment to Zymeworks, bringing total upfront and milestone payments from Jazz to $650 million, with up to $1.3 billion in additional milestones and tiered royalties of 10-20% on net sales remaining. This is the second FDA approval for zanidatamab in under two years, significantly de-risking the asset and providing substantial non-dilutive capital to fund Zymeworks' wholly-owned pipeline.
- FDA approved two Ziihera-containing regimens for first-line HER2+ GEA, including with and without tislelizumab plus chemotherapy.
- Zymeworks earned a $250 million milestone payment from Jazz Pharmaceuticals upon this approval.
- Total upfront and milestone payments received from Jazz now total $650 million.
- Zymeworks remains eligible for up to $1.3 billion in additional regulatory and commercial milestones plus tiered royalties of 10% to 20% on Jazz's net sales.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access